GBT Reports Third Quarter And 9M18 Results
MONTEVIDEO, Uruguay, Nov. 12, 2018 /PRNewswire/ -- Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced today its results for the 3Q18 and 9M18.
Net revenues for 3Q18 increased by 2% in constant currency, also impacted by discontinued business and SOLVADI®, marking BRL 829M LTM (including hyperinflation adjustment).
Gross profit rose by 16% vs. 3Q17, in constant currency.
Gross margin of 51% (including hyperinflation adjustments) vs. 50% in 3Q17.
Adjusted EBITDA grew by 34% in constant currency vs. 3Q17.
Adjusted EBITDA margin came to 24% in 3Q18 (including hyperinflation adjustment), improving 283 bps vs. 3Q17.
Net income totaled BRL 13M in 3Q18 (including hyperinflation adjustment) from a loss of BRL 8M in 3Q17.
Adjusted net income up 82% from 3Q17, in constant currency.
Launches of new products continue to be main focus.
+55 11 5090-5927
SOURCE Grupo Biotoscana
Upcoming Life Sciences Events
- April 2019
- London: BioTrinity 2019
- May 2019
- Basel: Swiss Biotech Day
- Shanghai: Pharma - Biotech Product and Company Valuation Workshop